Business Context and Reporting Period
This Form 8-K Current Report was filed by Verastem, Inc. on January 7, 2020. The filing primarily discloses the entry into a material definitive agreement and provides Regulation FD disclosure regarding upcoming investor meetings at the 38th Annual J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. However, it discloses specific financial obligations related to a new agreement:
- Upfront Payment: A non-refundable payment of $3,000,000 is due to Chugai Pharmaceutical Co., Ltd. by February 21, 2020.
- Royalties: The Company is obligated to pay double-digit royalties on net sales of products containing the licensed compound.
- Liquidity and Debt: No specific liquidity ratios, cash balances, or debt levels are reported in this document.
Material Changes
The primary material change reported is the execution of an exclusive, worldwide license agreement with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing CH5126766 (CKI27), a dual RAF/MEK inhibitor. This agreement grants Verastem exclusive rights to develop the compound at its own cost and expense.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference starting January 13, 2020. A slide presentation regarding the company's strategy and the new agreement is attached as Exhibit 99.1.
Risks and Contingencies:
- Opt-Back Rights: Chugai retains the right to opt back into development and commercialization in the European Union (upon FDA NDA submission) and in Japan and Taiwan (upon FDA marketing authorization). If exercised, Chugai must reimburse Verastem for development costs to-date.
- Termination: Verastem may terminate the agreement with 180 days' written notice. Chugai may terminate if Verastem challenges licensed patents. Either party may terminate for material breach or insolvency.
- Regulatory Status: The information provided in the presentation is not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the $3,000,000 upfront payment on the Company's current cash position and liquidity.
- Review the attached Exhibit 99.1 presentation for specific clinical data or development timelines for CH5126766 (CKI27).
- Assess the potential financial impact of Chugai exercising its opt-back rights in the EU, Japan, or Taiwan.
- Confirm the Company's ability to fund the "at its own cost and expense" development obligations outlined in the agreement.